Particularly, the effectiveness of alisertib and panobinostat to reduce migration could be observed across different CLL subgroups (Fig. S6), including mutated IgHV (blue, 3/3), unmutated IgHV (gray, 3/5) and p53-deficient CLL (black, 8/9). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.